Page last updated: 2024-10-16

carnitine and Syndrome

carnitine has been researched along with Syndrome in 48 studies

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
"Propofol infusion syndrome is a rare but frequently fatal complication in critically ill children given long-term propofol infusions."7.71Impaired fatty acid oxidation in propofol infusion syndrome. ( Segar, P; Shield, J; Stone, J; Weir, P; Wolf, A, 2001)
"A patient with carnitine deficiency syndrome for tracheostomy and resection of tracheal granuloma was anesthetized with nitrous oxide and sevoflurane and vecuronium bromide."7.68[Anesthesia in a patient with carnitine deficiency syndrome]. ( Andoh, T; Kurahashi, K; Okumura, F; Sato, K; Yamazaki, S, 1993)
"The human primary carnitine deficiency syndromes are potentially fatal disorders affecting children and adults."7.67Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. ( Engel, AG; Rebouche, CJ, 1984)
"L-Carnitine is an essential cofactor in transfer of long-chain fatty acids across the inner mitochondrial membrane."6.36Carnitine metabolism and deficiency syndromes. ( Engel, AG; Rebouche, CJ, 1983)
" In addition to the typical findings of Norman-Roberts syndrome, case 1 had atrial septal defect, corpus callosum agenesis, intracranial widespread calcification and case 2 had bilateral macular cherry-red spot, persistent foramen ovale, increased blood level of C6 hexanoylcarnitine, cavum septum pellucidum vergae anomaly and cerebellar atrophy."3.72Report of two Turkish infants with Norman-Roberts syndrome. ( Caksen, H; Cinal, A; Fryns, JP; Kirimi, E; Odabaş, D; Tuncer, O; Unal, O; Uner, A, 2004)
"Propofol infusion syndrome is a rare but frequently fatal complication in critically ill children given long-term propofol infusions."3.71Impaired fatty acid oxidation in propofol infusion syndrome. ( Segar, P; Shield, J; Stone, J; Weir, P; Wolf, A, 2001)
"A patient with carnitine deficiency syndrome for tracheostomy and resection of tracheal granuloma was anesthetized with nitrous oxide and sevoflurane and vecuronium bromide."3.68[Anesthesia in a patient with carnitine deficiency syndrome]. ( Andoh, T; Kurahashi, K; Okumura, F; Sato, K; Yamazaki, S, 1993)
"The human primary carnitine deficiency syndromes are potentially fatal disorders affecting children and adults."3.67Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. ( Engel, AG; Rebouche, CJ, 1984)
"The syndrome of systemic carnitine deficiency (progressive muscle weakness, recurrent metabolic encephalopathy, low liver and muscle and fluctuating serum carnitine levels) has been attributed to a defect of carnitine biosynthesis."3.66In vitro analysis of hepatic carnitine biosynthesis in human systemic carnitine deficiency. ( Engel, AG; Rebouche, CJ, 1980)
"Fibromyalgia is a clinically defined chronic condition of unknown etiology characterized by chronic widespread pain that often co-exists with sleep disturbances, cognitive dysfunction and fatigue."2.58Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. ( Häuser, W; Klose, P; Üçeyler, N; Walitt, B; Welsch, P, 2018)
"Brugada syndrome is an autosomal dominant trait with right bundle branch block and ST elevation."2.43Pathogenesis of cardiac conduction disorders in children genetic and histopathologic aspects. ( Barness, LA; Gilbert-Barness, E, 2006)
"Many patients with chronic fatigue syndrome(CFS) fulfill the criteria of FMS and represent one end of a spectrum of presentation."2.40[Fibromyalgia syndrome]. ( Matsumoto, Y, 1999)
" These deal mainly with biochemical systems that are known to be affected by VPA, or with the possible idiosyncratic production of toxic VPA metabolites, especially delta 4-VPA."2.38Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. ( Levy, RH; Stephens, JR, 1992)
"Mitochondrial myopathies are clinically heterogeneous disorders that can affect multiple systems besides skeletal muscle (mitochondrial encephalomyopathies or cytopathies) and are usually defined by morphological abnormalities of muscle mitochondria."2.37Mitochondrial myopathies. ( Bonilla, E; DeVivo, DC; DiMauro, S; Nakagawa, M; Zeviani, M, 1985)
"L-Carnitine is an essential cofactor in transfer of long-chain fatty acids across the inner mitochondrial membrane."2.36Carnitine metabolism and deficiency syndromes. ( Engel, AG; Rebouche, CJ, 1983)
"Hyperammonemia is a rare, often fatal complication after transplantation."1.43Hyperammonemia Syndrome After Lung Transplantation: A Single Center Experience. ( Bain, KB; Byers, DE; Chen, C; Hachem, RR; Iuppa, JA; Patterson, GA; Trulock, EP; Witt, CA; Yusen, RD, 2016)
"At 6 weeks of age she started with convulsions reaching up to 20 myoclonic seizures a day."1.34[Glucose transponer type 1 deficiency síndrome (GLUT-1 SD) treated with ketogenic diet. Report of one case]. ( Cabello, JF; Colombo, MC; Cornejo, VE; Raimann, EB, 2007)
"Barth syndrome is an X-linked recessive condition characterized by skeletal myopathy, cardiomyopathy, proportionate short stature, and recurrent neutropenia, but with normal cognitive function."1.29Barth syndrome: clinical observations and genetic linkage studies. ( Becker, LE; Bridge, PJ; Christodoulou, J; Clarke, JT; Jay, V; Lehotay, DC; McInnes, RR; Platt, BA; Robinson, BH; Wilson, G, 1994)
"Carnitine deficiency was found in skeletal muscle."1.26Carnitine deficiency of skeletal muscle: report of a treated case. ( Angelini, C; Cantarutti, F; Lücke, S, 1976)

Research

Studies (48)

TimeframeStudies, this research(%)All Research%
pre-199024 (50.00)18.7374
1990's10 (20.83)18.2507
2000's8 (16.67)29.6817
2010's4 (8.33)24.3611
2020's2 (4.17)2.80

Authors

AuthorsStudies
Sokolova, LP1
Starykh, EV1
Qutob, HMH1
Saad, RA1
Bali, H1
Osailan, A1
Jaber, J1
Alzahrani, E1
Alyami, J1
Elsayed, H1
Alserihi, R1
Shaikhomar, OA1
Divya, KM1
Savitha, DP1
Krishna, GA1
Dhanya, TM1
Mohanan, PV1
Shah, SF1
Jafry, AT1
Hussain, G1
Kazim, AH1
Ali, M1
Rivani, E1
Endraswari, PD1
Widodo, ADW1
Khalil, MR1
Guldberg, R1
Nørgård, BM1
Uldbjerg, N1
Wehberg, S1
Fowobaje, KR1
Mashood, LO1
Ekholuenetale, M1
Ibidoja, OJ1
Romagnoli, A1
D'Agostino, M1
Pavoni, E1
Ardiccioni, C1
Motta, S1
Crippa, P1
Biagetti, G1
Notarstefano, V1
Rexha, J1
Perta, N1
Barocci, S1
Costabile, BK1
Colasurdo, G1
Caucci, S1
Mencarelli, D1
Turchetti, C1
Farina, M1
Pierantoni, L1
La Teana, A1
Al Hadi, R1
Cicconardi, F1
Chinappi, M1
Trucchi, E1
Mancia, F1
Menzo, S1
Morozzo Della Rocca, B1
D'Annessa, I1
Di Marino, D1
Choya, A1
de Rivas, B1
Gutiérrez-Ortiz, JI1
López-Fonseca, R1
Xu, S1
Cheng, B1
Huang, Z1
Liu, T1
Li, Y1
Jiang, L1
Guo, W1
Xiong, J1
Amirazodi, M1
Daryanoosh, F1
Mehrabi, A1
Gaeini, A1
Koushkie Jahromi, M1
Salesi, M1
Zarifkar, AH1
Studeny, P1
Netukova, M1
Nemcokova, M1
Klimesova, YM1
Krizova, D1
Kang, H1
Tao, Y1
Zhang, Q1
Sha, D1
Chen, Y1
Yao, J1
Gao, Y1
Liu, J1
Ji, L1
Shi, P1
Shi, C1
Wu, YL1
Wright, AI1
M El-Metwaly, N1
A Katouah, H1
El-Desouky, MG1
El-Bindary, AA1
El-Bindary, MA1
Kostakis, ID1
Raptis, DA1
Davidson, BR1
Iype, S1
Nasralla, D1
Imber, C1
Sharma, D1
Pissanou, T1
Pollok, JM1
Hughes, AM1
Sanderson, E1
Morris, T1
Ayorech, Z1
Tesli, M1
Ask, H1
Reichborn-Kjennerud, T1
Andreassen, OA1
Magnus, P1
Helgeland, Ø1
Johansson, S1
Njølstad, P1
Davey Smith, G1
Havdahl, A1
Howe, LD1
Davies, NM1
Amrillah, T1
Prasetio, A1
Supandi, AR1
Sidiq, DH1
Putra, FS1
Nugroho, MA1
Salsabilla, Z1
Azmi, R1
Grammatikopoulos, P1
Bouloumis, T1
Steinhauer, S1
Mironov, VS2
Bazhenova, TA2
Manakin, YV2
Yagubskii, EB2
Yakushev, IA1
Gilmutdinov, IF1
Simonov, SV1
Lan, K1
Yang, H1
Zheng, J1
Hu, H1
Zhu, T1
Zou, X1
Hu, B1
Liu, H1
Olokede, O1
Wu, H2
Holtzapple, M1
Gungor, O1
Kose, M1
Ghaemi, R1
Acker, M1
Stosic, A1
Jacobs, R1
Selvaganapathy, PR1
Ludwig, N1
Yerneni, SS1
Azambuja, JH1
Pietrowska, M1
Widłak, P1
Hinck, CS1
Głuszko, A1
Szczepański, MJ1
Kärmer, T1
Kallinger, I1
Schulz, D1
Bauer, RJ1
Spanier, G1
Spoerl, S1
Meier, JK1
Ettl, T1
Razzo, BM1
Reichert, TE1
Hinck, AP1
Whiteside, TL1
Wei, ZL1
Juan, W1
Tong, D1
Juan, LX1
Sa, LY1
Jie, HFM1
Xiao, G1
Xiang, LG1
Jie, HM1
Xu, C1
Yu, DN1
Yao, ZX1
Bigdeli, F1
Gao, XM1
Cheng, X1
Li, JZ1
Zhang, JW1
Wang, W2
Guan, ZJ1
Bu, Y1
Liu, KG1
Morsali, A1
Das, R1
Paul, R1
Parui, A1
Shrotri, A1
Atzori, C1
Lomachenko, KA1
Singh, AK1
Mondal, J1
Peter, SC1
Florimbio, AR1
Coughlin, LN1
Bauermeister, JA1
Young, SD1
Zimmerman, MA1
Walton, MA1
Bonar, EE1
Demir, D1
Balci, AB1
Kahraman, N1
Sunbul, SA1
Gucu, A1
Seker, IB1
Badem, S1
Yuksel, A1
Ozyazicioglu, AF1
Goncu, MT1
Zhang, H1
Zhou, H1
Deng, Z1
Luo, L1
Ong, SP1
Wang, C1
Xin, H1
Whittingham, MS1
Zhou, G1
Maemura, R1
Wakamatsu, M1
Matsumoto, K1
Sakaguchi, H1
Yoshida, N1
Hama, A1
Yoshida, T1
Miwata, S1
Kitazawa, H1
Narita, K1
Kataoka, S1
Ichikawa, D1
Hamada, M1
Taniguchi, R1
Suzuki, K1
Kawashima, N1
Nishikawa, E1
Narita, A1
Okuno, Y1
Nishio, N1
Kato, K1
Kojima, S1
Morita, K1
Muramatsu, H1
Takahashi, Y1
Yirgu, A1
Mekonnen, Y1
Eyado, A1
Staropoli, A1
Vinale, F1
Zac, J1
Zac, S1
Pérez-Padilla, R1
Remigio-Luna, A1
Guzmán-Boulloud, N1
Gochicoa-Rangel, L1
Guzmán-Valderrábano, C1
Thirión-Romero, I1
Statsenko, ME1
Turkina, SV1
Barantsevich, ER1
Karakulova, YV1
Baranova, NS1
Morzhukhina, MV1
Wang, Q1
Gu, Y1
Chen, C2
Qiao, L1
Pan, F1
Song, C1
Canetto, SS1
Entilli, L1
Cerbo, I1
Cipolletta, S1
Wu, Y3
Zhu, P1
Jiang, Y1
Zhang, X1
Wang, Z1
Xie, B1
Song, T1
Zhang, F1
Luo, A1
Li, S1
Xiong, X1
Han, J1
Peng, X1
Li, M1
Huang, L1
Chen, Q1
Fang, W1
Hou, Y1
Zhu, Y1
Ye, J1
Liu, L1
Islam, MR1
Sanderson, P1
Johansen, MP1
Payne, TE1
Naidu, R1
Cao, J1
Yang, J1
Niu, X1
Liu, X1
Zhai, Y1
Qiang, C1
Niu, Y1
Li, Z1
Dong, N1
Wen, B1
Ouyang, Z1
Zhang, Y2
Li, J2
Zhao, M1
Zhao, J1
Morici, P1
Rizzato, C1
Ghelardi, E1
Rossolini, GM1
Lupetti, A1
Gözüküçük, R1
Cakiroglu, B1
He, X1
Li, R1
Zhao, D2
Zhang, L1
Ji, X1
Fan, X1
Chen, J1
Wang, Y1
Luo, Y1
Zheng, D1
Xie, L1
Sun, S1
Cai, Z1
Liu, Q1
Ma, K1
Sun, X1
Drinkwater, JJ1
Davis, TME1
Turner, AW1
Davis, WA1
Suzuki, Y1
Mizuta, Y1
Mikagi, A1
Misawa-Suzuki, T1
Tsuchido, Y1
Sugaya, T1
Hashimoto, T1
Ema, K1
Hayashita, T1
Welsch, P1
Üçeyler, N1
Klose, P1
Walitt, B1
Häuser, W1
Han, L1
He, Z1
Zhang, J1
Liu, Z1
Fang, F1
Ding, C1
Lyu, J1
Bain, KB1
Iuppa, JA1
Yusen, RD1
Byers, DE1
Patterson, GA1
Trulock, EP1
Hachem, RR1
Witt, CA1
Rico Corral, MA1
de la Vega Vázquez, JM1
Holgado Silva, C1
Aznar Martín, A1
Zamora Madaría, E1
BORNICHE, P1
CANLORBE, P1
NECCHIDELLASILVA, A1
SEVERGNINI, B1
Bok, LA1
Vreken, P1
Wijburg, FA1
Wanders, RJ1
Gregersen, N1
Corydon, MJ1
Waterham, HR1
Duran, M1
Caksen, H1
Tuncer, O1
Kirimi, E1
Fryns, JP1
Uner, A1
Unal, O1
Cinal, A1
Odabaş, D1
McLoughlin, LM1
Trimble, ER1
Jackson, P1
Chong, SK1
Uezono, S1
Hotta, Y1
Takakuwa, Y1
Ozaki, M1
Gilbert-Barness, E1
Barness, LA1
Cornejo, VE1
Cabello, JF1
Colombo, MC1
Raimann, EB1
De la Morena, E1
Montero, C1
Barth, PG1
Scholte, HR1
Berden, JA1
Van der Klei-Van Moorsel, JM1
Luyt-Houwen, IE1
Van 't Veer-Korthof, ET1
Van der Harten, JJ1
Sobotka-Plojhar, MA1
Kaeser, HE1
Rebouche, CJ4
Engel, AG6
Ziegan, J1
Kühn, HJ1
Lössner, J1
Künnert, B1
Lehmann, J1
Cumming, WJ1
McCarty, MF1
Stagnaro-Neri, M1
Stagnaro, S1
Christodoulou, J1
McInnes, RR1
Jay, V1
Wilson, G1
Becker, LE1
Lehotay, DC1
Platt, BA1
Bridge, PJ1
Robinson, BH1
Clarke, JT1
Kurahashi, K1
Andoh, T1
Sato, K1
Yamazaki, S1
Okumura, F1
Takahira, T1
Utsunomiya, T1
Ishijima, M1
Mori, H1
Yano, K1
Nunobiki, T1
Eto, H1
Powell, BR1
Budden, SS1
Buist, NR1
Feoli-Fonseca, JC1
Lambert, M1
Mitchell, G1
Melançon, SB1
Dallaire, L1
Millington, DS1
Qureshi, IA1
Matsumoto, Y1
Wolf, A1
Weir, P1
Segar, P1
Stone, J1
Shield, J1
Jerusalem, F1
Spiess, H1
Baumgartner, G1
Bradley, WG1
Tomlinson, BE1
Hardy, M1
Scarlato, G2
Pellegrini, G1
Cerri, C2
Meola, G2
Veicsteinas, A1
Caccia, MR1
Gravame, V1
Pagni, R1
Scarpini, E1
Banker, BQ1
Eiben, RM1
Angelini, C2
Lücke, S1
Cantarutti, F1
Stephens, JR1
Levy, RH1
Kobayakawa, H1
Shinzato, T1
Maeda, K1
Voit, T1
Kramer, H1
Thomas, C1
Wechsler, W1
Reichmann, H1
Lenard, HG1
Byrne, E1
Trounce, I1
Grinio, LP1
Hokland, B1
Madsen, S1
DiMauro, S1
Bonilla, E1
Zeviani, M1
Nakagawa, M1
DeVivo, DC1
Yderstraede, KB1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075]Phase 142 participants Interventional2003-09-30Completed
Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453]Phase 1/Phase 240 participants (Actual)Interventional2008-04-30Completed
Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266]Phase 294 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)

(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months

Interventiong (Mean)
Lean Mass BaselineLean Mass 3 monthsLean Mass 6 monthsFat Mass BaselineFat Mass 3 monthsFat Mass 6 months
SMA Type 14317.154993.925133.833011.373618.254316.08

Max CMAP Amplitude (Mean)

The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmV (Mean)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment2.282.32
Cohort 1b Sitters Treatment2.932.37
Cohort 2 Standers and Walkers - Treatment5.526.56

Max CMAP Amplitude Median

The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmV (Median)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment1.911.44
Cohort 1b Sitters Treatment2.21.8
Cohort 2 Standers and Walkers - Treatment5.35.85

Max CMAP Area (Mean)

The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmVms (Mean)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment5.465.28
Cohort 1b Sitters Treatment5.455.26
Cohort 2 Standers and Walkers - Treatment14.8516.26

Max CMAP Area (Median)

The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmVms (Median)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment3.63.74
Cohort 1b Sitters Treatment4.63.4
Cohort 2 Standers and Walkers - Treatment13.6516.85

Modified Hammersmith Change From Baseline to 6 Months

Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months

,
InterventionScore (Mean)
Baseline visit (0 weeks)6 Month visit (V2)Change from Baseline
Cohort 1a Sitters Placebo Then Treatment20.020.60.6
Cohort 1b Sitters Treatment16.616.80.2

Modified Hammersmith Extend Baseline

"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)

InterventionScore (Mean)
Modified Hammersmith Extend at S1 (-4 weeks)Modified Hammersmith Extend at S2 (0 weeks)
Cohort 2 Experimental47.048.3

Reviews

10 reviews available for carnitine and Syndrome

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
    The Cochrane database of systematic reviews, 2018, 02-28, Volume: 2

    Topics: Adrenergic Uptake Inhibitors; Adult; Carnitine; Cyclopropanes; Desvenlafaxine Succinate; Duloxetine

2018
[SUCLA2-related encephalomyopathic mitochondrial DNA depletion syndrome: a case report and review of literature].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2014, Volume: 52, Issue:11

    Topics: Carnitine; Child; DNA, Mitochondrial; Dystonia; Europe; Female; Homozygote; Humans; Magnetic Resonan

2014
Pathogenesis of cardiac conduction disorders in children genetic and histopathologic aspects.
    American journal of medical genetics. Part A, 2006, Oct-01, Volume: 140, Issue:19

    Topics: Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Carnitine; Female; Heart Block; Heart Conduction

2006
Drug-induced myasthenic syndromes.
    Acta neurologica Scandinavica. Supplementum, 1984, Volume: 100

    Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Autoimmune Diseas

1984
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
Carnitine metabolism and deficiency syndromes.
    Mayo Clinic proceedings, 1983, Volume: 58, Issue:8

    Topics: Adolescent; Adult; Aged; Brain Diseases; Carnitine; Chemical Phenomena; Chemistry; Child; Child, Pre

1983
[Fibromyalgia syndrome].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:2

    Topics: Biomarkers; Carnitine; Diagnosis, Differential; Fatigue; Fatigue Syndrome, Chronic; Fibromyalgia; Hu

1999
Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.
    Pharmaceutisch weekblad. Scientific edition, 1992, Jun-19, Volume: 14, Issue:3A

    Topics: Ammonia; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Humans; Liver; Liver Diseases;

1992
[Human syndromes of carnitine deficiency (a review)].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1988, Volume: 88, Issue:8

    Topics: Carnitine; Child; Humans; Liver; Muscles; Syndrome

1988
Mitochondrial myopathies.
    Annals of neurology, 1985, Volume: 17, Issue:6

    Topics: Carnitine; Carnitine O-Palmitoyltransferase; Cytochromes; DNA, Mitochondrial; Humans; Microscopy, El

1985

Trials

2 trials available for carnitine and Syndrome

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022
Chronic sodium benzoate therapy in children with inborn errors of urea synthesis: effect on carnitine metabolism and ammonia nitrogen removal.
    Biochemical and molecular medicine, 1996, Volume: 57, Issue:1

    Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Ammonia; Benzoates; Benzoic Acid; Carnitine

1996

Other Studies

37 other studies available for carnitine and Syndrome

ArticleYear
[Asthenic syndrome in general therapeutic practice].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:4

    Topics: Asthenia; Carnitine; Humans; Syndrome

2022
Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Amino Acids; Biliary Atresia; Biomarkers; Carnitine; Chromatography, Liquid; Demography; Discriminan

2014
Hyperammonemia Syndrome After Lung Transplantation: A Single Center Experience.
    Transplantation, 2016, Volume: 100, Issue:3

    Topics: Aged; Ammonia; Arginine; Biomarkers; Carnitine; Combined Modality Therapy; Decontamination; Female;

2016
[Carnitine deficiency myopathy: a case of late diagnosis].
    Anales de medicina interna (Madrid, Spain : 1984), 2002, Volume: 19, Issue:8

    Topics: Adult; Carnitine; Female; Humans; Lipid Metabolism, Inborn Errors; Muscular Diseases; Syndrome

2002
[Clinical and humoral action of carnitine in the syndromes of post-infectious malnutrition in infancy].
    Clinica chimica acta; international journal of clinical chemistry, 1960, Volume: 5

    Topics: Carnitine; Child; Folic Acid; Humans; Infant; Infant Nutrition Disorders; Infections; Malnutrition;

1960
[ON TREATMENT OF DYSPROTIDEMIC SYNDROMES IN GERIATRICS].
    Giornale di gerontologia, 1965, Volume: 13

    Topics: Anabolic Agents; Blood Protein Disorders; Carnitine; Geriatrics; Humans; Lysine; Steroids; Syndrome;

1965
Short-chain Acyl-CoA dehydrogenase deficiency: studies in a large family adding to the complexity of the disorder.
    Pediatrics, 2003, Volume: 112, Issue:5

    Topics: Amino Acid Substitution; Anemia, Hemolytic; Butyryl-CoA Dehydrogenase; Carnitine; Consanguinity; DNA

2003
Report of two Turkish infants with Norman-Roberts syndrome.
    Genetic counseling (Geneva, Switzerland), 2004, Volume: 15, Issue:1

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atrophy; Brain; Carnitine; Cell Movement; Cerebellum

2004
L-carnitine in cyclical vomiting syndrome.
    Archives of disease in childhood, 2004, Volume: 89, Issue:12

    Topics: Antiemetics; Carnitine; Child; Humans; Male; Syndrome; Vomiting

2004
Acquired carnitine deficiency: a clinical model for propofol infusion syndrome?
    Anesthesiology, 2005, Volume: 103, Issue:4

    Topics: Adult; Anesthetics, Intravenous; Carnitine; Fatty Acids; Humans; Mitochondria; Oxidation-Reduction;

2005
[Glucose transponer type 1 deficiency síndrome (GLUT-1 SD) treated with ketogenic diet. Report of one case].
    Revista medica de Chile, 2007, Volume: 135, Issue:5

    Topics: Anticonvulsants; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Carnitine; Dietary Fats; Ery

2007
Low serum L-carnitine concentrations in toxic oil syndrome.
    Lancet (London, England), 1982, Apr-17, Volume: 1, Issue:8277

    Topics: Carnitine; Female; Humans; Male; Oils; Spain; Syndrome

1982
An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes.
    Journal of the neurological sciences, 1983, Volume: 62, Issue:1-3

    Topics: Adenosine Triphosphatases; Adult; Aged; Ca(2+) Mg(2+)-ATPase; Cardiomyopathies; Carnitine; Cytochrom

1983
[Carnitine deficiency myopathy].
    Acta histochemica. Supplementband, 1984, Volume: 30

    Topics: Adult; Carnitine; Female; Histocytochemistry; Humans; Middle Aged; Mitochondria, Muscle; Muscles; Mu

1984
Carnitine metabolism and inborn errors.
    Journal of inherited metabolic disease, 1984, Volume: 7 Suppl 1

    Topics: Carnitine; Child; Female; Humans; Male; Metabolism, Inborn Errors; Muscles; Syndrome

1984
Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport.
    The Journal of clinical investigation, 1984, Volume: 73, Issue:3

    Topics: Adult; Biological Transport; Carnitine; Child; Child, Preschool; Circadian Rhythm; Diet; Extracellul

1984
Lipid myopathy. Case report and review.
    Journal of the neurological sciences, 1984, Volume: 64, Issue:1

    Topics: Adult; Animals; Carnitine; Diagnosis, Differential; Humans; Lipid Metabolism; Male; Muscles; Neuromu

1984
A note on "orthomolecular aids for dieting"--myasthenic syndrome due to dl-carnitine.
    Medical hypotheses, 1982, Volume: 9, Issue:6

    Topics: Animals; Anuria; Carnitine; Humans; Neuromuscular Diseases; Obesity; Rats; Syndrome

1982
In vitro analysis of hepatic carnitine biosynthesis in human systemic carnitine deficiency.
    Clinica chimica acta; international journal of clinical chemistry, 1980, Oct-09, Volume: 106, Issue:3

    Topics: Adolescent; Adult; Aldehyde Oxidoreductases; Aldehyde-Lyases; Betaine; Carnitine; Child; Child, Pres

1980
[Percussion-auscultation syndrome of carnitine deficiency].
    La Clinica terapeutica, 1994, Volume: 145, Issue:8

    Topics: Adult; Aged; Auscultation; Carnitine; Environmental Monitoring; Female; Humans; Male; Middle Aged; P

1994
Barth syndrome: clinical observations and genetic linkage studies.
    American journal of medical genetics, 1994, Apr-15, Volume: 50, Issue:3

    Topics: Abnormalities, Multiple; Acids; Cardiomyopathy, Dilated; Carnitine; Diseases in Twins; Dwarfism; Ele

1994
[Anesthesia in a patient with carnitine deficiency syndrome].
    Masui. The Japanese journal of anesthesiology, 1993, Volume: 42, Issue:8

    Topics: Adolescent; Anesthesia, General; Carnitine; Ethers; Female; Granuloma; Humans; Methyl Ethers; Nitrou

1993
Specific myocardial disease caused by multisystemic triglyceride storage in Jordans' anomaly.
    American heart journal, 1993, Volume: 126, Issue:4

    Topics: Adult; Cardiomyopathy, Dilated; Carnitine; Female; Humans; Leukocytes; Lipid Metabolism, Inborn Erro

1993
Dominantly inherited megalencephaly, muscle weakness, and myoliposis: a carnitine-deficient myopathy within the spectrum of the Ruvalcaba-Myhre-Smith syndrome.
    The Journal of pediatrics, 1993, Volume: 123, Issue:1

    Topics: Abnormalities, Multiple; Administration, Oral; Biopsy, Needle; Brain; Carnitine; Child; Child, Presc

1993
Impaired fatty acid oxidation in propofol infusion syndrome.
    Lancet (London, England), 2001, Feb-24, Volume: 357, Issue:9256

    Topics: Acidosis; Carnitine; Critical Care; Electron Transport; Fatty Acids; Hemofiltration; Humans; Hypnoti

2001
Lipid storage myopathy with normal carnitine levels.
    Journal of the neurological sciences, 1975, Volume: 24, Issue:3

    Topics: Acetyltransferases; Acid Phosphatase; Adenosine Triphosphatases; Adult; Carnitine; Electromyography;

1975
Further studies of mitochondrial and lipid storage myopathies.
    Journal of the neurological sciences, 1978, Volume: 35, Issue:2-3

    Topics: Adolescent; Adult; Brain; Carnitine; Female; Humans; Lipidoses; Male; Middle Aged; Mitochondria, Mus

1978
The syndrome of carnitine deficiency: morphological and metabolic correlations in two cases.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1978, Volume: 5, Issue:2

    Topics: Adult; Carnitine; Child; Child, Preschool; Histocytochemistry; Humans; Liver; Male; Muscles; Muscula

1978
Myopathy with paroxysmal myoglobinuria and focal muscle necrosis following enfluorane anaesthesia.
    Journal of the neurological sciences, 1978, Volume: 39, Issue:1

    Topics: Adenylyl Cyclases; Adolescent; Carnitine; Carnitine O-Palmitoyltransferase; Enflurane; Glycogen; Hum

1978
Carnitine deficiency: clinical, morphological, and biochemical observations in a fatal case.
    Journal of neurology, neurosurgery, and psychiatry, 1977, Volume: 40, Issue:4

    Topics: Acidosis; Carnitine; Child; Hepatomegaly; Humans; Male; Mitochondria, Muscle; Muscles; Muscular Dise

1977
Carnitine deficiency of skeletal muscle: report of a treated case.
    Neurology, 1976, Volume: 26, Issue:7

    Topics: Carnitine; Child; Female; Humans; Mitochondria, Muscle; Muscles; Muscular Diseases; Syndrome; Vacuol

1976
[Dialysis-associated disequilibrium syndrome and the prevention and therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50 Suppl

    Topics: Animals; Autonomic Nervous System Diseases; Brain Edema; Carnitine; Humans; Hyponatremia; Hypotensio

1992
Myopathy in Williams-Beuren syndrome.
    European journal of pediatrics, 1991, Volume: 150, Issue:7

    Topics: Adult; Biopsy; Carnitine; Child; Child, Preschool; Contracture; Face; Female; Heart Defects, Congeni

1991
Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle.
    Journal of neurology, neurosurgery, and psychiatry, 1987, Volume: 50, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Asthenia; Carnitine; Chronic Disease; Electron Transport Complex IV;

1987
[Carnitine deficiency syndromes].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1986, Nov-10, Volume: 106, Issue:31

    Topics: Carnitine; Humans; Syndrome

1986
[Carnitine. Deficiency syndromes and their treatment].
    Ugeskrift for laeger, 1985, Dec-09, Volume: 147, Issue:50

    Topics: Carnitine; Humans; Lipid Metabolism; Metabolic Diseases; Syndrome

1985
Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome.
    Science (New York, N.Y.), 1973, Mar-02, Volume: 179, Issue:4076

    Topics: Acyltransferases; Adult; Carbon Isotopes; Carnitine; Coenzyme A Ligases; Fatty Acids; Female; Humans

1973